The physiological effect of disease targeted therapy in PAH
Research type
Research Study
Full title
The physiological effect of disease targeted therapy in pulmonary arterial hypertension
IRAS ID
201870
Contact name
Martin Johnson
Contact email
Sponsor organisation
NHS National Waiting Times Board
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Pulmonary hypertension (high blood pressure in the lungs) results in reduced exercise capacity and consequently reduced quality of life. Drugs in pulmonary hypertension aim to open up the blood vessels in the lungs (pulmonary arteries) and therefore reduce the strain on the heart. Recent evidence has shown that there are additional problems in pulmonary hypertension that affect exercise capacity. Muscle function in the limbs and breathing muscles is reduced, the nervous system controlling the blood pressure and heart rate response to exercise is less efficient and there are higher levels of inflammation in the blood. It is unclear how current drugs used for pulmonary hypertension affect these processes and therefore, whether new treatments are needed to address these specific abnormalities.
REC name
West of Scotland REC 4
REC reference
16/WS/0196
Date of REC Opinion
8 Nov 2016
REC opinion
Further Information Favourable Opinion